Plus Therapeutics jumps after FDA allows co to begin human trials for cancer therapy

Shares of drug developer Plus Therapeutics PSTV.O more than double to 38 cents

Co says the U.S. FDA has cleared its application to begin human trials for its experimental brain cancer therapy

The trial is funded by a $3 million research grant from the U.S. Department of Defense, co says

The early-stage trial is aimed to determine the maximum tolerated dose safety and tolerability of the therapy called Reyobiq in pediatric patients aged six to 21 years

The company is testing the therapy to treat aggressive brain tumors called high-grade glioma and ependymoma

Including session moves, stock down 68.1% YTD